Vol 5, No 23 (December 07, 2017): Annals of Translational Medicine

Column in Hypertension1

Comparative effectiveness and safety of empagliflozin on cardiovascular mortality and morbidity in adults with type 2 diabetes
Wilbert S. Aronow, Tatyana A. Shamliyan
Annals of Translational Medicine
 2017;
5
(23)
:455
Masked hypertension
Wilbert S. Aronow
Annals of Translational Medicine
 2017;
5
(23)
:456
Hypertension associated with atrial fibrillation
Wilbert S. Aronow
Annals of Translational Medicine
 2017;
5
(23)
:457

Original Article

Detection of MET amplification in gastroesophageal tumor specimens using IQFISH
Jan Trøst Jørgensen, Karsten Bork Nielsen, Jens Mollerup, Anna Jepsen, Ning Go
Annals of Translational Medicine
 2017;
5
(23)
:458

Editorial

River blindness goes beyond the eye: autoimmune antibodies, cross-reactive with Onchocerca volvulus antigen, detected in brain of patients with Nodding syndrome
Christoph Kaiser, Sébastien D. S. Pion
Annals of Translational Medicine
 2017;
5
(23)
:459
Alectinib in untreated anaplastic lymphoma kinase-positive nonsmall cell lung cancer
Anne-Marie Ruppert, Xavier Mignard, Marie Wislez
Annals of Translational Medicine
 2017;
5
(23)
:460
New evidence for nodding disease as an autoimmune reaction to Onchocerca volvulus
Michael J. Boivin
Annals of Translational Medicine
 2017;
5
(23)
:461
Antibody-drug conjugate targeting protein tyrosine kinase 7, a receptor tyrosine kinase-like molecule involved in WNT and vascular endothelial growth factor signaling: effects on cancer stem cells, tumor microenvironment and whole-body homeostasis
Masaru Katoh
Annals of Translational Medicine
 2017;
5
(23)
:462
Creative technology advances tissue preservation
Mandi J. Lopez
Annals of Translational Medicine
 2017;
5
(23)
:463
Drugs targeting protease-activated receptor-4 improve the antithrombotic therapeutic window
Shauna L. French, Justin R. Hamilton
Annals of Translational Medicine
 2017;
5
(23)
:464
Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction
Ahsan A. Khan, Gregory Y. H. Lip
Annals of Translational Medicine
 2017;
5
(23)
:465
Prediction models to advance individualized resuscitation in trauma hemorrhage and acute traumatic coagulopathy (ATC): even the longest journey starts with first steps—Lao-Tzu (Chinese philosopher)
Marc Maegele
Annals of Translational Medicine
 2017;
5
(23)
:466
Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4—a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors
Denira Imamovic, Semir Vranic
Annals of Translational Medicine
 2017;
5
(23)
:467
Predictors of response and resistance to checkpoint inhibitors in solid tumors
Sanjana V. Rao, Amy E. Moran, Julie N. Graff
Annals of Translational Medicine
 2017;
5
(23)
:468
Nrf2: a promising trove for diabetic wound healing
Amruta Jindam, Veera Ganesh Yerra, Ashutosh Kumar
Annals of Translational Medicine
 2017;
5
(23)
:469
Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes
Hidekatsu Yanai
Annals of Translational Medicine
 2017;
5
(23)
:470
Lysosomal function in β-cell survival during glucolipotoxicity
Ana Batista- Gonzalez, Rajat Singh
Annals of Translational Medicine
 2017;
5
(23)
:471
Telomeric zinc-finger associated protein (TZAP): a new player in telomere diseases?
Benedetta Donati, Luca Valenti
Annals of Translational Medicine
 2017;
5
(23)
:472
Canagliflozin lowers blood sugar, but does it also lower cardiovascular risk? Maybe not
Thomas F. Heston, Anndres H. Olson, Nicholas R. Randall
Annals of Translational Medicine
 2017;
5
(23)
:473
Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors: SGLT2 inhibitors in the real world
Richard J. MacIsaac, Elif I. Ekinci
Annals of Translational Medicine
 2017;
5
(23)
:474
Semaglutide—the “new kid on the block” in the field of glucagonlike peptide-1 receptor agonists?
Cristian Guja, Rucsandra Dănciulescu Miulescu
Annals of Translational Medicine
 2017;
5
(23)
:475
Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists—what will REWIND add?
Keith C. Ferdinand, Indrajeet Mahata
Annals of Translational Medicine
 2017;
5
(23)
:476
The ODYSSEY DM-DYSLIPIDEMIA trial: confirming the benefits of alirocumab in diabetic mixed dyslipidemia
Paul Chan, Li Shao, Brian Tomlinson, Zhong-Min Liu
Annals of Translational Medicine
 2017;
5
(23)
:477
Empagliflozin reduces albuminuria—a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial
Rikke Borg, Frederik Persson
Annals of Translational Medicine
 2017;
5
(23)
:478

Perspective

Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers
Bob T. Li, Dennis Stephens, Jamie E. Chaft, Charles M. Rudin, David R. Jones, Valerie W. Rusch, Andreas Rimner, James M. Isbell
Annals of Translational Medicine
 2017;
5
(23)
:479

Letter to the Editor

Radiation risk from lung cancer screening
Cristiano Rampinelli, Paolo De Marco, Massimo Bellomi
Annals of Translational Medicine
 2017;
5
(23)
:480

Disclosure:

1. The series “Column in Hypertension” was commissioned by the editorial office, Annals of Translational Medicine without any sponsorship or funding.